Kidney Cancer
FY23 Ad Hoc Programmatic Reviewers:
Michael Serzan, M.D.
Dana-Farber Cancer Institute
Last updated Tuesday, April 23, 2024
Michael Serzan, M.D.
Dana-Farber Cancer Institute
Last updated Tuesday, April 23, 2024